Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting

Journal of Medical Economics

Volumn 17, Issue 4, 2014, Pages 259-265

  Meissner, Brian ^a   Trivedi, Digisha ^b   You, Min ^b   Rosenblatt, Lisa ^b  

^a Bristol Myers Squibb   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

BDMARDs; Biologics; Healthcare costs; Switching

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; COST; ECONOMICS; INSURANCE; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COSTS AND COST ANALYSIS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84898993136     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.893241     Document Type: Article

References (13)

1. Helmick CG, Felson DT, Lawrence RC et al.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
2. Feely MG, Erickson A, O'Dell JR. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother 2009;10:2095-106
3. Zhang J, Shan Y, Reed G, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort. Arth Care Res 2011;63:1672-9
4. van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66:849-51
5. Oei HB, Hooker RS, Cipher DJ, et al. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009;27:926-34
6. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and antiadalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21
7. Hyrich KL, Lunt M, Watson KD et al.; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
8. Bombardieri S, Ruiz AA, Fardellone P et al.; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9
9. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29
10. Atzeni F, Sarzi-Puttini P, Gorla R, et al. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011;10:397-403
11. Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74
12. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
13. Greenberg JD, Reed G, Decktor D et al.; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42